Objective Osteopenia/osteoporosis is being increasingly reported as a complication of many
chronic diseases, even in children. In this preliminary study, we evaluated the effect of an …

Objectives. To determine the effects of once-weekly oral alendronate on indices of bone
size, density and resorption in children with chronic illness being treated with …

Aims: To evaluate the currently available evidence for the effectiveness of bisphosphonates
in children with low bone mineral density (BMD) and fragility fractures associated with …

The purpose of the investigation was to test the use of alendronate in the therapy of children
affected by chronic rheumatic diseases and symptomatic drug-induced osteoporosis. Two …

Study objective. To investigate the degree and determinants of osteopenia in juvenile
chronic polyarthritis. Design. Retrospective case-control study of central bone mineral …

Objective To assess bone mineral status in a group of children with systemic type juvenile
chronic arthritis (JCA), which places them at high risk to develop osteoporosis. Methods …

Objective To evaluate the continued efficacy and safety of alendronate (ALN) for up to 2
years in patients receiving glucocorticoids. Methods This is a 12‐month extension of a …

Osteoporosis is characterized by loss of both bone mass and microarchitectural integrity,
resulting in an increased risk of fractures with associated morbidity and mortality. Awareness …

Osteoporosis is now increasingly recognized in children due to the increased prevalence of
disorders associated with bone loss. Fragility fractures represent the cardinal clinical …

Osteoporosis is increasingly being seen in young people. The primitive forms are relatively
rare, but the secondary forms—particularly in long-term corticosteroid therapy—are a …